Table 1 Baseline characteristics of the included patients with RD or RB
Study (year) | Design | Number of patients | M/F ratio | Mean age | Associated Pathologies | Follow-up | Worsening in visual acuity | Number of RD or RB | Retinal Reattachment | Type of RD or RB | Intervention | Clinical Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Moreira (2018) | Retrospective | 22 | 13/9 | 28.5 | Proliferative Vitreoretinopathy (5/22); | 64.9 months | 2 | 22 | 20/22 | RRD (22/22) | RSB (4/22); PPV + GAS(1/22); PPV + SO(4/22); RSB + GAS (3/10); RSB + PPV + SO (10/22) | NA |
Lucena (2009) | Retrospective | 10 | 3/7 | 38 | NA | NA | 3 | 10 | 10/10 | RD + RR (8/10); RRP (retinal rupture) (2/10) | Retinopexy + PPV (2/10); PPV (4/10); Retinopexy (2/10); Laser (2/10) | NA |
Kianersi (2012) | Retrospective | 5 | 1/4 | 27 | NA | 1 month | 5 | 5 | 5/5 | RRD (3/5) + TRD (1/5) + Unknow URD (1/5) | PPV + lensectomy(1/5); SB + Crypexia (1/5); SB (2/5); PPV + SO(1/5) | Antiparasitics with corticosteroids (oral and topical), mydriatic agents (4/5); None (1/5) |
Faridi (2015) | Retrospective | 28 | 14/14 | 40 | NA | 22.5 months | 3 | 4 | 4/4 | RRD (4/4) | PPV + PFO + MP + AFX + EL + SO—> PPV/ROSO/PPL/MP/EL/retinectomy/SB/C3F8—> PPV/MP/EL/PFO/300° retinectomy/AFX/long-acting SO tamponade (1/4); PPV/AFX/EL/SF6—> PPV/EL/AFX/SB/SF6—> PPV/retinectomy/PFO/AFX/EL/SO/CE IOL/PPV/ROSO—> PPV/270° retinectomy/AFX/EL/ long-acting SO tamponade—> PPV/ROSO/MP; PPV/AFX/EL/MP/SO (1/4); Laser retinopexy (1/4) | Oral Antibiotic therapy [sulfamethoxazole/trimethoprim (9/28), triple therapy: sulfadiazine, pyrimethamine, and folinic acid, (6/28), clindamycin (3/28), or azithromycin (1/28), unknown (9/28)]; Intravitreal Therapy [intravitreal clyndamicin and dexamethasone (2/4), intravitreal clyndamicin and triamcinolone (1/4), intravitreal triamcinolone (1/4)] |
Driessen (2000) | Retrospective | 150 | NA | 29.5 | Myopia + RB/RD (8/16); Myopia (35/134) | 7 years | 7 | 16 | 12/16 | RD (8/16); RD + RB(1/16); RB (7/16) | SB + PPV + SO (1/16); SB (2/16); SB + lensectomy (1/16); Cryopexia + SB (1/16); PPV + SO + lensectomy (1/16); Cryocogulations 1/16 + Abstained (2/16); Laser coagulation (7/16) | Antiparasitics with corticosteroids (4/16); Antiparasitics (3/16); Corticosteroids (2/16); None (7/16) |
Caplan (2023) | Retrospective | 420 | NA | 40.9 | Proliferative Vitreoretinopathy (4/13 RRD); | 3 months | N/A | 27 (16 analyzed) | 14/14 (14 analyzed in last follow-up) | RRD (13/16); TRD (3/16) | SB + SO (2/14); PPV + SO (7/14); PPV + SB + SO (5/14) | NA |
Adán (2009) | Retrospective | 15 | 8/7 | 37.2 | NA | 41.4 months | 0 | 8 | 8/8 | RRD (6/8); RRD + TRD (2/8) | SB + PPV + SO (1/8); SB + PPV + delamination + GAS (1/8); SB + PPV + lensectomy + SO (2/8); SB + PPV + GAS (4/8) | Trimethoprim/sulfamethoxazole and oral prednisone at tapering doses for 30–40 days |
Study (year) | Design | M:F | Age | Associated Pathologies | Follow- up | Worsening in visual acuity | – | Anatomical closure | Type of RD or RB | Intervention | Clinical Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
Scott (2018) | Case report | M | 27 | NA | 5 months | YES | – | YES | Retinal tear + RRD | SB + PPV + GAS | Trimethoprim/sulfamethoxazole (160 mg/800 mg) twice daily and clindamycin 300 mg three times daily, as well as topical glucocorticoids and a mydriatic agent. One week later, he initiated systemic oral glucocorticoid therapy (prednisone 60 mg daily) with a scheduled taper |
Erol (2021) | Case report | F | 30 | NA | 2 months | YES | – | YES | MH + RD | PPV | Trimethoprim/sulfamethoxazole (160/800 mg) twice a day and clindamycin 300 mg four times a day. After three days, 32 mg/day methylprednisolone was added to oral treatment |